RA Capital

Eliem Therapeutics

climbbio.com

Immune-mediated diseases impact 1 in 7 people and are increasing in prevalence worldwide. They occur when the immune system mistakenly attacks the tissues of the body and can result in permanent organ damage or even death. Despite advances in treatment, many patients with immune-mediated diseases suffer from poor outcomes when their disease cannot be controlled with available therapies. At Climb Bio, we believe that we can impact the pathways that cause immune-mediated diseases to give patients precious time free of disease.